ADTX
Aditxt, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.01
+7.35%Jul 17, 2026, 00:00 UTC
Aditxt, Inc. amended its private placement of senior secured notes, adding a new investor, cancelling one existing note, and issuing two new additional notes with no net change to the aggregate principal amount.
Jun 23, 2026, 00:00 UTC
Aditxt, Inc. amended its Note Purchase Agreement to increase the aggregate original principal amount of senior secured convertible notes from $6,254,355.17 to $6,638,970.55 and added a new investor.
Jun 10, 2026, 11:56 UTC
Aditxt plans to spin off its wholly owned subsidiary Ignite into an independent public company via a newly formed holding company expected to be named Ignite Proteomics Inc.
Source:Jun 9, 2026, 11:45 UTC
Aditxt signed a definitive business combination agreement valuing its subsidiary Ignite Proteomics at approximately $150 million.
Jun 9, 2026, 00:00 UTC
Aditxt, Inc. and its wholly owned subsidiary Ignite Proteomics LLC issued senior secured convertible notes with an aggregate principal of approximately $5,169,444.44 in a private placement exempt from registration under Section 4(a)(2) and Rule 506(b) of Regulation D, with proceeds allocated to commercial services and general corporate purposes.
Jun 1, 2026, 00:00 UTC
Jeffrey M. Busch was appointed as Interim Chief Executive Officer of Aditxt, Inc.
Jun 1, 2026, 00:00 UTC
Rowena Albanna resigned as Chief Operating Officer of Aditxt, Inc., effective June 5, 2026.
Jun 1, 2026, 00:00 UTC
Shahrokh Shabahang resigned as a member of the Board of Directors of Aditxt, Inc., effective May 31, 2026.